Logos Global Management LP made a significant move on February 17, 2026, by disclosing in a Securities and Exchange Commission filing that it purchased 1,100,000 shares of Immunovant (NASDAQ:IMVT) for an estimated $24.53 million. This transaction marked a substantial increase in the firm’s position in Immunovant, adding to its existing stake.
The total position grew by approximately $6.1 million in value over the quarter, reflecting both the new shares acquired and the movement in the stock price. By the end of the quarter, Logos held 1,375,000 shares of Immunovant, valued at around $34.95 million, accounting for 2.11% of the fund’s assets under management (AUM) and placing it outside the fund’s top five holdings.
According to the Securities and Exchange Commission (SEC) filing dated February 17, 2026, Logos Global Management LP increased its stake in Immunovant by 1,100,000 shares during the fourth quarter of 2025, with an estimated transaction value of $24.4 million based on average closing prices. The value of the stake at quarter-end rose by $6.1 million, reflecting both trading activity and market price changes.
After the purchase, Immunovant represented 2.11% of the fund’s 13F assets under management (AUM). The top holdings after the filing included NASDAQ:RVMD at $238.50 million (14.4% of AUM), NASDAQ:PRAX at $110.53 million (6.7% of AUM), NASDAQ:IDYA at $108.03 million (6.5% of AUM), NASDAQ:OLMA at $80.22 million (4.9% of AUM), and NASDAQ:CDTX at $68.48 million (4.1% of AUM).
As of March 13, 2026, Immunovant’s shares were priced at $24.72, marking a 29.3% increase over the past year and outperforming the S&P 500 by 10.58%. Immunovant, a subsidiary of Roivant Sciences (NASDAQ: ROIV), focuses on monoclonal antibody therapeutics for autoimmune diseases. Its lead candidate, batoclimab, has completed Phase III trials in myasthenia gravis and is currently in ongoing Phase III trials for thyroid eye disease, with results expected in the first half of 2026.
It’s important to note that Immunovant has no approved products yet, and its revenue depends entirely on successful clinical and regulatory outcomes. Logos Global Management is a San Francisco-based, healthcare-focused hedge fund known for its concentrated, research-driven approach in life sciences and biotech. The firm conducts thorough scientific and regulatory due diligence before making investment decisions in the sector.
The acquisition of a significant number of shares in Immunovant by Logos Global Management LP is a notable move due to its scale. The fund nearly quintupled its stake in the company, adding 1.1 million shares for an estimated $24.5 million, bringing the total investment to approximately $35 million. This demonstrates a meaningful commitment to the stock, with Immunovant now accounting for about 2% of the fund’s AUM, up from 0.4%.
For individual investors, it’s essential to view this transaction as a research prompt rather than a buy signal. Clinical-stage biotech companies like Immunovant carry significant binary risk, and institutional conviction in such investments is typically based on in-depth diligence that retail investors may not have access to. It’s crucial to monitor the upcoming batoclimab thyroid eye disease readout, with topline data from Phase 3 TED studies expected in the first half of 2026, as this will shape Immunovant’s regulatory path.
Before considering investing in Immunovant, it’s recommended to conduct thorough research and consider expert advice. The Motley Fool Stock Advisor analyst team recently identified the 10 best stocks for investors to buy now, none of which included Immunovant. These top stock picks have the potential to generate significant returns in the coming years, as evidenced by the historical performance of past recommendations.
In conclusion, Logos Global Management LP’s strategic investment in Immunovant highlights its confidence in the company’s potential and the broader biotech sector. This move underscores the importance of thorough research and due diligence when considering investments in healthcare and biotech companies.
